[go: up one dir, main page]

ATE547395T1 - Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors - Google Patents

Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors

Info

Publication number
ATE547395T1
ATE547395T1 AT04730206T AT04730206T ATE547395T1 AT E547395 T1 ATE547395 T1 AT E547395T1 AT 04730206 T AT04730206 T AT 04730206T AT 04730206 T AT04730206 T AT 04730206T AT E547395 T1 ATE547395 T1 AT E547395T1
Authority
AT
Austria
Prior art keywords
sphingosine
modulators
phosphate receptor
aminopropanol derivatives
aminopropanol
Prior art date
Application number
AT04730206T
Other languages
English (en)
Inventor
Klaus Hinterding
Carsten Spanka
Frederic Zecri
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329500A external-priority patent/GB0329500D0/en
Priority claimed from GB0329505A external-priority patent/GB0329505D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE547395T1 publication Critical patent/ATE547395T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/72Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/094Esters of phosphoric acids with arylalkanols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574Esters of oxyacids of phosphorus
    • C07F9/65744Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
AT04730206T 2003-04-30 2004-04-29 Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors ATE547395T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0309944 2003-04-30
GB0329500A GB0329500D0 (en) 2003-12-19 2003-12-19 Organic compounds
GB0329505A GB0329505D0 (en) 2003-12-19 2003-12-19 Organic compounds
PCT/EP2004/004569 WO2004096752A1 (en) 2003-04-30 2004-04-29 Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator

Publications (1)

Publication Number Publication Date
ATE547395T1 true ATE547395T1 (de) 2012-03-15

Family

ID=33424535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04730206T ATE547395T1 (de) 2003-04-30 2004-04-29 Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors

Country Status (11)

Country Link
US (1) US7625950B2 (de)
EP (1) EP1622860B1 (de)
JP (1) JP4603531B2 (de)
CN (1) CN1777575B (de)
AT (1) ATE547395T1 (de)
AU (1) AU2004234066B2 (de)
BR (1) BRPI0410025A (de)
CA (1) CA2523582A1 (de)
ES (1) ES2383298T3 (de)
MX (1) MXPA05011596A (de)
WO (1) WO2004096752A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241790B2 (en) 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
GB0313612D0 (en) * 2003-06-12 2003-07-16 Novartis Ag Organic compounds
AU2004268052B2 (en) 2003-08-28 2009-11-19 Novartis Ag Aminopropanol derivatives
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
WO2006001463A1 (ja) * 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. S1p受容体結合能を有する化合物およびその用途
RU2396982C2 (ru) * 2004-07-16 2010-08-20 Киорин Фармасьютикал Ко., Лтд. Эффективный способ использования лекарственных средств и способ предотвращения выраженности побочных эффектов
MX2007001661A (es) 2004-08-13 2007-04-23 Praecis Pharm Inc Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
ES2563034T3 (es) 2004-10-12 2016-03-10 Kyorin Pharmaceutical Co., Ltd. Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol e hidratos del mismo, e intermedios para la producción de los mismos
CA2596990A1 (en) 2005-02-14 2006-08-24 University Of Virginia Patent Foundation Sphingosine 1-phosphate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
GB0513431D0 (en) 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
EP1932522B1 (de) * 2005-10-07 2012-05-23 Kyorin Pharmaceutical Co., Ltd. Therapeutisches Mittel gegen Lebererkrankungen mit einem 2-Amino-1,3-propandiol-Derivat als Wirkstoff
AU2006325931B8 (en) 2005-12-15 2012-09-20 Mitsubishi Tanabe Pharma Corporation Amine compound and use thereof for medical purposes
RU2008134702A (ru) 2006-01-27 2010-03-10 Юниверсити Оф Вирждиния Пэтент Фаундейшн (Us) Способ лечения невропатической боли
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2641718A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
US8097644B2 (en) 2006-03-28 2012-01-17 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist
JP5140593B2 (ja) 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
HRP20131172T1 (hr) * 2006-08-08 2014-01-17 Kyorin Pharmaceutical Co., Ltd. Esterski derivat aminofosforne kiseline i modulator receptora s1p koji sadrži isti kao aktivni sastojak
EP2097397A1 (de) 2006-11-21 2009-09-09 University Of Virginia Patent Foundation Tetralin-analoge mit sphingosin-1-phosphat-agonisten-aktivität
AU2007323557A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
WO2008064320A2 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
BRPI0813683A2 (pt) * 2007-06-14 2019-09-24 Mitsubishi Tanabe Pharma Corp composto amina e uso farmacêutico do mesmo
KR20100067677A (ko) 2007-09-24 2010-06-21 알러간, 인코포레이티드 스핑고신-1-포스페이트 (sp1) 생물학적 활성을 갖는 아릴 또는 헤테로아릴 기를 함유하는 인돌 화합물
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
RU2010149311A (ru) 2008-05-08 2012-06-20 Аллерган, Инк. (Us) ТЕРАПЕВТИЧЕСКИ ПОЛЕЗНЫЕ ЗАМЕЩЕННЫЕ 1,7-ДИФЕНИЛ-1,2,3,5,6,7-ГЕКСАГИДРОПИРИДО [3,2,1-ij]ХИНОЛИНОВЫЕ СОЕДИНЕНИЯ
US8143291B2 (en) 2008-05-09 2012-03-27 Allergan, Inc. Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity
KR20190004843A (ko) 2008-07-23 2019-01-14 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[b]인돌-3-일)아세트산 유도체
AU2009288738B9 (en) 2008-08-27 2015-04-16 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
EP2491023B1 (de) * 2009-10-23 2014-12-31 Allergan, Inc. Cumarinverbindungen und deren therapeutische verwendung als rezeptormodulatoren
BR122013016024A2 (pt) * 2009-12-10 2016-05-10 Novartis Ag composições, usos, kit e processos de preparação relacionados com derivados halogenados de fty720
SG10201500639TA (en) 2010-01-27 2015-03-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
SG183416A1 (en) 2010-03-03 2012-09-27 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
CN102260178A (zh) * 2010-05-25 2011-11-30 中国医学科学院药物研究所 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
CN119751336A (zh) 2018-09-06 2025-04-04 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3870419B2 (ja) * 1994-08-22 2007-01-17 三菱ウェルファーマ株式会社 ベンゼン化合物およびその医薬としての用途
GB2309868A (en) * 1996-01-30 1997-08-06 Sony Corp Radio receiver detects FCCH synchronising signal
AU735853B2 (en) * 1997-04-04 2001-07-19 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compound, Pharmaceutical use thereof and synthetic intermediates therefor
JP2001519808A (ja) 1997-04-10 2001-10-23 ファルマシア・アンド・アップジョン・カンパニー ポリ芳香族抗菌組成物
CZ20032560A3 (cs) * 2001-03-26 2003-12-17 Novartis Ag Deriváty 2-aminopropanolu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
JP2002316985A (ja) * 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US6963012B2 (en) * 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
BRPI0212894B8 (pt) * 2001-09-27 2021-05-25 Kyorin Seiyaku Kk composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica
AU2003273865A1 (en) * 2002-09-13 2004-04-30 Novartis Ag Amino-propanol derivatives

Also Published As

Publication number Publication date
JP2006524660A (ja) 2006-11-02
EP1622860B1 (de) 2012-02-29
BRPI0410025A (pt) 2006-04-25
AU2004234066B2 (en) 2008-02-21
WO2004096752A1 (en) 2004-11-11
AU2004234066A1 (en) 2004-11-11
ES2383298T3 (es) 2012-06-20
JP4603531B2 (ja) 2010-12-22
CN1777575B (zh) 2010-05-12
US20060211658A1 (en) 2006-09-21
MXPA05011596A (es) 2006-01-23
CA2523582A1 (en) 2004-11-11
US7625950B2 (en) 2009-12-01
CN1777575A (zh) 2006-05-24
EP1622860A1 (de) 2006-02-08

Similar Documents

Publication Publication Date Title
ATE547395T1 (de) Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors
MXPA05011597A (es) Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina.
SE0202133D0 (sv) Novel compounds
TW200617009A (en) Organic compounds
ES2335410T8 (es) Derivados de aminopropanol.
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
TW200626579A (en) Inhibitors of the interaction between MDM2 and p53
ATE470665T1 (de) Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
ATE433447T1 (de) Pyrimiidinverbindungen
ATE542799T1 (de) Chinolinonderivate als parp und tank-inhibitoren
TW200801003A (en) Novel compounds
MXPA05013348A (es) Derivados de amino-propanol como moduladores del receptor de esfingosina-1-fosfato.
SE0401762D0 (sv) Novel compounds
TW200635921A (en) Organic compounds
SE0303541D0 (sv) New compounds
JO2704B1 (en) Interference inhibition factors between MD2 and B53
ES2368594T3 (es) Derivados sustituidos de ciclohexilmetilo.
SE0400850D0 (sv) Novel Compounds
DE602006015215D1 (de) Prolinamidderivate als natriumkanalmodulatoren
BRPI0511610A (pt) derivados de amino-propanol
BRPI0519292A2 (pt) compostos orgÂnicos
SE0403085D0 (sv) Novel componds
MXPA05010651A (es) Compuestos de pirazol.
ATE541839T1 (de) Pyrrolidiniumderivate als m3-muskarinische rezeptoren
TW200740781A (en) Novel compounds